Ovarian Hyperstimulation Syndrome
Conditions
Keywords
ovarian hyperstimulation syndrome, Montelukast
Brief summary
montelukast & dydrgesteron will be given to cases with suspected or proven ovarian hyperstimulation in one group in comparison with dydrogesteron alone in the other group.
Detailed description
patients with high risk for ovarian hyperstimulation will undergo a freeze-all protocol then montelukast & dydrgesteron will be given to cases with suspected or proven ovarian hyperstimulation in one group in comparison with dydrogesteron alone in the other group.
Interventions
DRUGdydrgesterone 10 mg( tab)/12hs/14 days
Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup
COMBINATION_PRODUCTmontelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days
montelukast 10 mg(tab) once daily oral for 7 days & dydrgesterone 10 mg (tab) twice daily oral for 14 days &
Sponsors
Hawaa Fertility Center
Benha University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 37 Years
Healthy volunteers
No
Inclusion criteria
* PCOS high responders high numbers of ovum retrieved
Exclusion criteria
* hypersensitivity to any drug components phenylketonuria patients depression liver dysfunction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants who develop ovarian hyperstimulation syndrome | 0-14 days | incidence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants treated of ovarian hyperstimulation syndrome | 0-14 days | treatment & resolution |
Countries
Egypt
Outcome results
None listed